Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06238700 · ClinicalTrials.gov registry record · NA
Study on Allopregnanolone and Depression in Women Across the Menopause Transition
A NA study of Depression, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06238700: Recruiting NA study of Depression, sponsored by Brigham and Women's Hospital.
NCT06238700 is a NA study of Depression that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 80 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06238700, a NA study of Depression, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to identify how enhanced allopregnanolone activity (via pregnenolone) affects behavior and neurobiology that may underlie perimenopausal depression.
Primary Outcome
The Ruminative Responses Scale (RRS) comprises 22 items which ask how frequently the participant thinks certain statements when they feel depressed. Each item is scored from 1-4. Total scores range from 22-88 with higher scores indicating more severe rumination.
Conditions Studied
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT pregnenolone
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-05-14 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
What NCT06238700 shows while recruiting
NCT06238700 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT06238700 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06238700 about?
NCT06238700 is a clinical study titled "Study on Allopregnanolone and Depression in Women Across the Menopause Transition". This study aims to identify how enhanced allopregnanolone activity (via pregnenolone) affects behavior and neurobiology that may underlie perimenopausal depression.
What is the current status of trial NCT06238700?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-05-14. Estimated completion is 2027-08-31.
What conditions does trial NCT06238700 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT06238700?
The interventions under investigation include: placebo (OTHER), pregnenolone (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06238700?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06238700 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06238700's enrollment target sits among peer trials
80 373rd of 679 higher than 299 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy